Stock Financial Ratios, Dividends, Split History

RMTI / Rockwell Medical, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.94
Volume150,400.00
Market Cap ($M)307.50
Enterprise Value ($M)304.23
Book Value ($M)27.37
Book Value / Share0.53
Price / Book11.35
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 51,768,424
Common Shares Outstanding 51,768,424
Weighted Average Number Of Shares Outstanding Basic 51,067,412
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 51,067,412
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.79
Return on Assets (ROA)-0.31
Return on Equity (ROE)-0.49
Balance Sheet (mrq) ($M)
Assets51.96
Liabilities24.59
Quick Ratio4.23
Current Ratio5.24
Income Statement (mra) ($M)
Sales Revenue Goods Net57,300,281.00
Operating Income-25.92
Net Income-25.92
Earnings Per Share Basic-0.51
Earnings Per Share Diluted-0.51
Cash Flow Statement (mra) ($M)
Cash From Operations-21.11
Cash from Investing14.50
Cash from Financing14.50
Identifiers and Descriptors
CUSIP774374102
Central Index Key (CIK)1041024
Related CUSIPS
774374902 774374952

Split History

Stock splits are used by Rockwell Medical, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Rockwell Medical's (RMTI) CEO Rob Chioini on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2018 Results Earnings Conference Call May 10, 2018 4:30 PM ET (4-0)

These 6 Equity Factors Are Driving Stock Market Returns

2018-05-09 seekingalpha
Factor investing is the investment process by which investors harvest risk premia through exposure to certain factors underlying stock characteristics. (185-0)

BRIEF-Rockwell Medical Update On Calcitriol New Manufacturing Submission To FDA

2018-05-08 reuters
* ROCKWELL MEDICAL INC - FOR CALCITRIOL VITAMIN D INJECTION, FDA HAS PROVIDED TARGET DATE FOR A RESPONSE TO SUBMISSION OF NO LATER THAN AUG 19, 2018 (4-0)

Rockwell Medical's (RMTI) CEO Rob Chioini on Q4 2017 Results - Earnings Call Transcript

2018-03-16 seekingalpha
Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2017 Results Earnings Conference Call March 15, 2018 4:30 PM ET (4-0)

BRIEF-Rockwell Medical Signs Exclusive License Agreement With Comercializadora BioRenal SpA

2017-12-14 reuters
* ROCKWELL MEDICAL SIGNS EXCLUSIVE LICENSE AGREEMENT WITH COMERCIALIZADORA BIORENAL SPA TO COMMERCIALIZE TRIFERIC® IN CHILE (4-0)

CUSIP: 774374102